• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Current Front-Line Targeted Treatments in Ph+ ALL

Opinion
Video

Elias Jabbour, MD, provides an overview of the history of targeted agents and the use of tyrosine kinase inhibitors (TKIs) in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).

Related Videos
Antonio Urbina, MD
4 Experts are featured in this series
4 Experts are featured in this series
2 experts in this video
2 experts in this video
Drs Yelena Janjigian and Zev Wainberg | Background image credit: ipopba - stock.adobe.com
© 2025 MJH Life Sciences
AJMC®
All rights reserved.